Skip to content
Global Health logo

Global Health

MEDANTA NSE
₹1,402.00 +76.20 (+5.75%)
P/E
67.76
View as Markdown
MCP
Close 4 Nov 2026 ₹1,402.00 +121.30 +9.47% 1Y
Start ₹1,280.70

Key Fundamentals

SmallcapHealthcare ServicesHealthcare

Price-based figures as of · EPS basis: Consolidated · TTM

ROCE
17.40%
Debt to Equity
0.30
EPS (TTM)
₹20.69
Book Value
₹147.34
Market Cap
—
P/E (TTM)
67.76
P/B
9.52
ROE
15.20%
Dividend Yield
0.04%
EBITDA
₹1,018 Cr
52W High
₹1,544.00
52W Low
₹956.00
Day Range
₹1,326.60 – ₹1,423.60
Volume
23,78,788

Peer Comparison

Healthcare › Healthcare Services › Hospitals › Hospital

Global Health peer comparison
Apollo Hospitals
₹8,599.5059.18₹1,22,850 Cr13.040.24%21.20%17.40%₹26,430 Cr₹2,171 Cr
Max Healthcare Institute
₹927.1561.89₹89,301 Cr7.960.22%14.70%14.70%₹8,712 Cr₹1,457 Cr
Manipal Health Enterprises
₹667.2088.96₹86,479 Cr5.340.00%6.64%8.30%₹11,400 Cr₹906 Cr
Aster DM Healthcare
₹719.55117.00₹59,927 Cr14.910.44%11.30%11.60%₹4,876 Cr₹363 Cr
Fortis Healthcare
₹790.6556.96₹59,706 Cr6.030.13%11.20%13.40%₹9,506 Cr₹1,070 Cr
Narayana Hrudayalaya
₹1,931.5048.36₹39,090 Cr7.890.24%20.50%15.50%₹9,072 Cr₹816 Cr
Global Health (this company)
₹1,402.0067.76₹37,618 Cr9.520.04%15.20%17.40%₹4,683 Cr₹552 Cr
Median 7 companies₹927.1561.89₹59,927 Cr7.960.22%14.70%14.70%₹9,072 Cr₹906 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

42 Weak

Data confidence 100/100

Category scores

Quality
41
Weak
Returns, margins, earnings quality 22% weight
Valuation
30
Poor
Cheap vs sector & own history 24% weight
Growth
63
Good
Sales & profit trajectory 9% weight
Financial Health
50
Average
Solvency, leverage, coverage 9% weight
Momentum
38
Weak
Trend strength, vol-adjusted 12% weight
Ownership
54
Average
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

1
  • Company has delivered good profit growth of 80.7% CAGR over last 5 years

Weaknesses

1
  • Stock is trading at 9.04 times its book value

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallStrong Bullish3412
OscillatorsBearish342
Moving AveragesStrong Bullish0010

Key readings

RSI (14)
62.76
Neutral
MACD (12,26,9)
−12.63
Bullish
SMA (50)
1,373.52
Bullish
SMA (200)
1,246.03
Bullish

As of

Analyst Rating

Based on 16 analysts
BUY88%

14 of 16 analysts rate Buy, 2 Hold, 0 Sell.

As of

BUY
14
88%
HOLD
2
13%
SELL
0
0%

Growth Rate

From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.

Revenue

Revenue growth by window
10Y+12.30%
5Y+24.97%
3Y+17.62%
1Y+19.45%
TTM+21.26%

Net profit

Net profit growth by window
10Y+12.54%
5Y+80.39%
3Y+19.33%
1Y+15.18%
TTM+3.37%

Operating cash flow

Operating cash flow growth by window
10Y+12.09%
5Y+24.16%
3Y+3.45%
1Y+14.42%
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
10Y−0.69 pp
5Y+7.48 pp
3Y−2.42 pp
1Y−2.91 pp
TTM−3.38 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2016₹1,382 Cr
Mar 2018₹1,343 Cr
Mar 2019₹1,456 Cr
Mar 2020₹1,500 Cr
Mar 2021₹1,447 Cr
Mar 2022₹2,167 Cr
Mar 2023₹2,710 Cr
Mar 2024₹3,275 Cr
Mar 2025₹3,692 Cr
Mar 2026₹4,410 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2016₹170 Cr
Mar 2018₹33.00 Cr
Mar 2019₹51.00 Cr
Mar 2020₹36.00 Cr
Mar 2021₹29.00 Cr
Mar 2022₹196 Cr
Mar 2023₹326 Cr
Mar 2024₹478 Cr
Mar 2025₹481 Cr
Mar 2026₹554 Cr

Analyst Forecasts

Forecast For
Dec 26 consensus · EBITDA
₹306 Cr −22.3% vs Sep 26
Reported High Mean Low

AI Analysis — Bull vs Bear

Figures as of 4 Nov 2026
AI opinion · based on fundamentals
Risk high

Global Health Ltd (Medanta) trades at ₹1,402 as of 2026-11-04 with a market cap of ₹37,618 Cr. The company has delivered strong compounded sales growth of 18% over 3 years and profit CAGR of approximately 81% over 5 years, but the stock commands a premium valuation at a P/E of 67.76x and P/B of 9.52x, while TTM profit growth has flattened to 0%.

Bull Case 8
  • Exceptional 5-year compounded profit growth of 81% CAGR, reflecting a sustained earnings ramp-up from the company's hospital network expansion
  • Healthy 3-year compounded sales growth of 18% and TTM revenue growth of 21%, indicating continued top-line momentum
  • Conservative balance sheet with a debt-to-equity ratio of just 0.30, providing financial flexibility for future capacity additions
  • ROCE of 15.05% suggests the company is generating reasonable returns on total capital deployed, a positive sign for a capital-intensive hospital business
  • 3-year ROE averaging 16% demonstrates consistent value creation for equity shareholders over a medium-term horizon
  • 3-year stock CAGR of 21% has rewarded shareholders well over the medium term, reflecting market recognition of the company's growth trajectory
  • 10-year compounded sales growth of 12% and profit growth of 13% point to a durable, long-cycle growth business rather than a one-off earnings spike
  • The stock is trading roughly 9% below its 52-week high of ₹1,544, suggesting it has pulled back from peak levels and is not at a euphoric extreme
Bear Case 7
  • TTM profit growth has stalled at 0%, a sharp deceleration from the 19% 3-year CAGR and 81% 5-year CAGR, raising questions about earnings momentum
  • Price-to-book ratio of 9.52x is elevated; the stock trades at over 9 times book value, which prices in substantial future growth
  • Dividend yield of just 0.04% offers virtually no income return, meaning investors are entirely dependent on capital appreciation
  • Last-year ROE of 15% has dipped from the 3-year and 5-year average of 16%, hinting at possible margin pressure or dilution effects
  • 1-year stock CAGR of -2% indicates the market has been repricing the stock downward over the recent twelve months despite revenue growth
  • Current EPS of ₹20.69 against a price of ₹1,402 means the stock needs to deliver significant earnings acceleration to justify its valuation multiple
  • The wide 52-week range of ₹956 to ₹1,544 — a spread of about 61% — reflects high price volatility relative to many large-cap healthcare peers

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

9h ago

TL;DR: Global Health delivered a strong Q2FY27 with 38% profit growth, 34% revenue growth, and meaningful margin expansion to 25.2%. The ₹997 crore Ghaziabad expansion signals confidence in sustained demand but will weigh on near-term free cash flow. No visible headwinds emerged this quarter. The operating trend is clearly improving, and capacity additions position the company for continued growth if occupancy ramps as expected.

Positives 4
  • Net profit surges 38% YoY Nov 3

    Q2FY27 net profit rose 38.3% YoY to ₹2,191 million, reflecting strong operational execution and demand traction across hospital network.

  • Revenue grows 33.6% YoY Nov 3

    Revenue from operations increased 33.6% YoY to ₹14,690 million in Q2FY27, indicating robust patient volume and realization growth.

  • EBITDA margin expands 420 bps Nov 3

    Operating EBITDA margin expanded 420 basis points to 25.2% in Q2FY27, signaling improving cost efficiency and operating leverage.

Quarterly Results

₹ Cr
MEDANTA quarterly results, ₹ crore
Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Sales
780
844
836
809
861
957
943
931
1,031
1,099
1,121
1,159
1,304
1,469
Expenses
595
631
620
629
675
728
706
707
784
868
904
915
1,017
1,099
Operating Profit
184
213
216
179
186
228
238
225
247
231
217
244
287
370
OPM %
24%
25%
26%
22%
22%
24%
25%
24%
24%
21%
19%
21%
22%
25%
Other Income
15
21
18
27
22
18
16
−27
20
36
−15
37
22
24
Interest
18
20
18
18
18
16
16
15
14
17
22
27
27
28
Depreciation
40
43
44
45
47
49
48
49
45
50
61
67
69
71
PBT
141
171
172
143
144
181
189
133
208
200
120
187
213
295
Tax %
28%
27%
28%
11%
26%
28%
24%
24%
24%
21%
21%
24%
26%
26%
Net Profit
102
125
124
127
106
131
143
101
159
158
95
142
157
219
EPS (₹)
3.8
4.66
4.61
4.74
3.96
4.87
5.32
3.78
5.92
5.89
3.54
5.36
5.9
—

Sep 2026: from the results filed on 3 Nov 2026, ahead of the full statement, so some rows are blank.

Profit & Loss

₹ Cr
MEDANTA profit and loss, annual, ₹ crore
Particulars Mar 2016Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
1,382
1,343
1,456
1,500
1,447
2,167
2,710
3,275
3,692
4,410
4,683
Expenses
1,081
1,218
1,283
1,309
1,250
1,709
2,073
2,466
2,806
3,480
3,705
Operating Profit
301
125
172
192
197
458
637
809
886
930
979
OPM %
22%
9%
12%
13%
14%
21%
24%
25%
24%
21%
21%
Other Income
45
49
50
44
31
39
49
75
29
98.59
80
Interest
14
28
38
57
73
86
86
84
74
90
92
Depreciation
70
86
102
115
123
130
150
173
194
223
246
PBT
262
60
83
64
32
281
449
627
647
715
720
Tax %
35%
45%
38%
43%
11%
30%
27%
24%
26%
23%
—
Net Profit
170
33
51
36
29
196
326
478
481
554
552
EPS (₹)
35.1
6.78
10.44
7.36
5.81
7.75
12.16
17.81
17.92
20.7
20.69
Div. Payout %
0%
0%
0%
0%
0%
0%
0%
0%
0%
2%
—

Balance Sheet

₹ Cr
MEDANTA balance sheet, annual, ₹ crore
Particulars Mar 2016Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
48
48
49
49
50
51
54
54
54
54
Reserves
976
1,136
1,246
1,300
1,333
1,565
2,375
2,852
3,333
3,908
Borrowings
165
456
787
929
931
1,109
1,122
802
718
1,190
Other Liabilities
295
343
347
388
380
421
547
572
662
753
Total Liabilities
1,485
1,984
2,430
2,666
2,694
3,146
4,097
4,280
4,766
5,905
Fixed Assets
914
1,094
1,194
1,703
1,616
1,776
2,050
2,236
2,514
3,795
CWIP
12
317
666
382
464
439
327
388
533
132
Investments
0
0
0
0
0
0
0
0
3
3
Other Assets
559
573
570
581
615
930
1,720
1,656
1,716
1,975
Total Assets
1,485
1,984
2,430
2,666
2,694
3,146
4,097
4,280
4,766
5,905

Cash Flow

₹ Cr
MEDANTA cash flow, annual, ₹ crore
Particulars Mar 2016Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
228
63
166
175
242
311
645
612
624
714
Investing
−241
−69
−249
−87
−239
−421
−342
−441
−721
−1,089
Financing
−7
9
97
−1
−81
160
346
−514
−97
272
Net Cash Flow
−20
3
14
87
−78
50
648
−343
−194
−103
Free Cash Flow
71
−81
−133
−13
100
38
409
335
110
−123
CFO/OP
108
93
135
121
131
89
118
98
89
90

Ratios

MEDANTA financial ratios, annual
Particulars Mar 2016Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
20
41
41
36
34
30
26
24
29
34
Inventory Days
28
26
26
43
42
36
35
32
28
29
Days Payable
92
124
142
147
138
90
114
90
81
89
Cash Conversion Cycle
−45
−56
−75
−67
−62
−24
−52
−34
−24
−26
Working Capital Days
−23
−33
−18
−31
−48
−20
−37
−32
−21
−7
ROCE %
—
—
6%
6%
5%
15%
17%
20%
20%
17%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Global Health insights

62 extracted metrics across FY16–FY27.

Shareholding Pattern

As of Sep 2026

  • Others 34.68%
  • Promoters 33.00%
  • DIIs 17.01%
  • FIIs 9.91%
  • Public 5.40%

No promoter shares pledged as of 14 Oct 2026

Change vs previous quarter

Not shown for some quarters: Others. Not available separately for this quarter: the shareholding filing gives Public and Others as one figure, shown under Public, so Others is left blank rather than estimated.

Documents

Frequently Asked Questions about Global Health

What does Global Health Ltd do?
Global Health Limited is one of the largest private multi-specialty tertiary care providers operating in the North and East regions of India. The company has key specialties in cardiology and cardiac science, neurosciences, oncology, digestive and hepatobiliary sciences, orthopedics, liver…
Where is Global Health Ltd (MEDANTA) listed?
Global Health Ltd trades as MEDANTA on the NSE and under code 543654 on the BSE.
Which sector does Global Health Ltd belong to?
Global Health Ltd is classified under the Healthcare Services sector, in the Hospitals industry.
What is the PE ratio of Global Health Ltd?
Global Health Ltd trades at a PE ratio of 67.76 as of 4 Nov 2026, on earnings per share of ₹20.69, against a book value of ₹147.34 per share.
What is the 52-week high and low of Global Health Ltd?
Over the last 52 weeks Global Health Ltd has traded between ₹956 and ₹1,544 as of 4 Nov 2026.
Does Global Health Ltd pay dividends?
Global Health Ltd has a dividend yield of 0.04%.
What is the Return on Equity (ROE) of Global Health Ltd?
Global Health Ltd reported a return on equity of 15.20%. Its debt-to-equity ratio is 0.30.

Company Information

Global Health Limited is one of the largest private multi-specialty tertiary care providers operating in the North and East regions of India. The company has key specialties in cardiology and cardiac science, neurosciences, oncology, digestive and hepatobiliary sciences, orthopedics, liver transplant, and kidney and urology.

Website medanta.org
Listed 16 Nov 2022
Face Value ₹2

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/MEDANTA.md for Global Health Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Hospital & Healthcare Services stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month